NCT04115683

Brief Summary

The aim of study is to analyze the effects of dual task training on balance, gait, cognition and neurotrophic factors in Parkinson's disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for not_applicable parkinson-disease

Timeline
Completed

Started Oct 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 4, 2019

Completed
12 days until next milestone

Study Start

First participant enrolled

October 16, 2019

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2021

Completed
Last Updated

November 18, 2019

Status Verified

November 1, 2019

Enrollment Period

1.5 years

First QC Date

September 30, 2019

Last Update Submit

November 15, 2019

Conditions

Outcome Measures

Primary Outcomes (11)

  • Balance-Postural Stability

    Postural Stability will be evaluated with Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York).. Postural Stability test will performed on both feet and on the left and right foot separately. Total stability index score will obtained as the test result.

    8 weeks

  • Balance- Limits of Stability

    Limits of Stability will be evaluated with Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Limits of Stability test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. Total direction control score will obtained as the test result.

    8 weeks

  • Balance- Modified Sensory Organization Tests

    Modified Sensory Organization Tests will be evaluated Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces; condition 1: eyes open-firm surface, condition 2: eyes closed-firm surface, condition 3: eyes open-foam surface and condition 4: eyes closed-foam surface. Stability index scores will obtained as the test result.

    8 weeks

  • Gait Speed

    Gait speed will be evaluated by using the BTS-G Walk system and recorded as m/min. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.

    8 weeks

  • Cadence

    Cadence will be evaluated by using the BTS-G Walk system and recorded as strides/min. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.

    8 weeks

  • Stride width

    Stride width will be evaluated by using the BTS-G Walk system and recorded as meters. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.

    8 weeks

  • Stride length

    Stride length will be evaluated by using the BTS-G Walk system and recorded as meters. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.

    8 weeks

  • Montreal Cognitive Assessment (MoCA)

    Montreal Cognitive Assessment (MoCA) will be used in order to evaluate cognition. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.It' score ranged from 0 to 30 and higher points indicates better cognitive outcomes.

    8 weeks

  • Change in brain derived neurotrophic factor (BDNF) levels of serum

    Brain derived neurotrophic factor (BDNF) levels of serum will be measured by using sandwich enzyme-linked immunosorbent assay (ELISA) kit.

    8 weeks

  • Change in vascular endothelial growth factor (VEGF) levels of serum

    Vascular endothelial growth factor (VEGF) levels of serum will be measured by using sandwich enzyme-linked immunosorbent assay (ELISA) kit.

    8 weeks

  • Change in insulin like growth factor 1 (IGF-1) levels of serum

    Insulin like growth factor 1 (IGF-1) levels of serum will be measured by using sandwich enzyme-linked immunosorbent assay (ELISA) kit.

    8 weeks

Secondary Outcomes (9)

  • Hoehn and Yahr Scale for level of physical disability in Parkinson's disease.

    8 weeks

  • Unified Parkinson's Disease Rating Scale (UPDRS)

    8 weeks

  • Berg Balance Scale (BBS)

    8 weeks

  • One-legged Stance Test

    8 weeks

  • Timed Up and Go (TUG) test

    8 weeks

  • +4 more secondary outcomes

Study Arms (2)

Intervention Group

EXPERIMENTAL
Other: Dual Task Training

Control Group

ACTIVE COMPARATOR
Other: Single Task Training

Interventions

45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.

Intervention Group

45 minutes of single task training consisting of same motor activities (walking, balance... etc.)

Control Group

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • at least 40 years of age
  • neurologist-diagnosed Parkinson's Disease
  • Hoehn \& Yahr (H\&Y) stages 1 to 3
  • or more mini mental status examination score.

You may not qualify if:

  • other neurologic disorder
  • cardiovascular, inflammatory,vestibular or musculoskeletal problems that could prevent them to participate in an exercise program
  • had deep brain stimulation history
  • visual, auditory, orientational problems that could affect study results

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gazi University, Faculty of Health Sciences

Ankara, 06560, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Çağrı Gülşen, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 30, 2019

First Posted

October 4, 2019

Study Start

October 16, 2019

Primary Completion

March 30, 2021

Study Completion

June 30, 2021

Last Updated

November 18, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

Locations